| Literature DB >> 21437437 |
Thales Paulo Batista1, Bernardo David Sabat, Paulo Sérgio V Melo, Luiz Eduardo C Miranda, Olival Cirilo L Fonseca-Neto, Américo Gusmão Amorim, Cláudio Moura Lacerda.
Abstract
OBJECTIVE: To analyze the impact of model for end-stage liver disease (MELD) allocation policy on survival outcomes after liver transplantation (LT).Entities:
Mesh:
Year: 2011 PMID: 21437437 PMCID: PMC3044564 DOI: 10.1590/s1807-59322011000100011
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Descriptive statistics of measured variables.
| Study Cohorts Median (interquartile range) or n (%) | ||||
| Variables | Overall Median (interquartile range) or n (%) | Pre‐MELD | Post‐MELD | p‐value |
| Recipient age (years) | 54 (44.5‐60.5) | 52 (45‐59) | 55 (44‐61) | 0.207 |
| MELD Score | 15 (12‐19) | 15 (12‐17) | 15 (12‐20) | 0.073 |
| HCC | 13 (10‐15) | 13 (12‐16) | 13 (10‐15) | 0.501 |
| Non‐HCC | 17 (13‐20) | 15 (11‐17) | 18.5 (14‐21.5) | <0.001 |
| Gender | 0.858 | |||
| Male | 137 (65.86) | 47 (64.38) | 90 (66.66) | |
| Female | 71 (34.13) | 26 (35.61) | 45 (33.33) | |
| ABO blood group | 0.953 | |||
| A | 84 (40.38) | 32 (43.83) | 52 (38.51) | |
| B | 24 (11.53) | 7 (9.58) | 17 (12.59) | |
| AB | 11 (5.28) | 2 (2.73) | 9 (6.66) | |
| O | 89 (42.78) | 32 (43.83) | 57 (42.22) | |
| Child‐Pugh class | 0.926 | |||
| A | 53 (25.48) | 17 (23.28) | 36 (26.66) | |
| B | 94 (45.19) | 37 (50.68) | 57 (42.22) | |
| C | 61 (29.32) | 19 (26.02) | 42 (31.11) | |
| Diagnosis | ||||
| Chronic viral hepatitis | 86 (41.34) | 32 (43.83) | 54 (40) | 0.697 |
| HCC | 61 (29.32) | 10 (13.69) | 51 (37.77) | <0.001 |
| Alcoholic cirrhosis | 53 (25.48) | 21 (28.76) | 32 (23.70) | 0.526 |
| Cryptogenic cirrhosis | 25 (12.01) | 10 (1.36) | 15 (11.11) | 0.745 |
| Autoimmune chronic Hepatitis | 13 (6.25) | 6 (2.88) | 7 (5.18) | 0.385 |
| Cholestatic liver Disease | 11 (5.28) | 3 (1.44) | 8 (5.92) | 0.750 |
| Miscellaneous | 51 (24.51) | 16 (21.91) | 35 (25.92) | 0.636 |
| Monthly transplant rate | 6 (4‐8) | 4 (3‐6) | 6 (5‐8) | <0.001 |
| Donor age (years) | 40.5 (25.5‐51) | 42 (26‐51) | 39 (25‐51) | 0.974 |
| Cold ischemia time (hours) | 6.8 (5.4‐8.7) | 7 (5.6‐8.6) | 6.6 (5.4‐8.7) | 0.533 |
| Warm ischemia time (minutes) | 47.5 (40‐55) | 55 (45‐60) | 45 (37‐51) | <0.001 |
| Red blood cells Transfusion (units) | 3 (1‐5) | 3 (2‐5) | 3 (1‐5) | 0.626 |
| Platelets transfusion (units) | 0 (0‐9) | 0 (0‐7) | 0 (0‐10) | 0.666 |
| Hepato‐venous reconstruction | 0.039 | |||
| Conventional | 127 (61.06) | 52 (71.23) | 75 (55.56) | |
| Piggyback | 81 (38.94) | 21 (28.77) | 60 (44.44) | |
Comparisons between Pre‐ vs. Post‐MELD cohorts using the Mann‐Whitney U‐test for continuous variables or chi‐square tests for categorical variables
Categories were not mutually exclusive, so multiple diagnoses were possible.
Primary biliary cirrhosis and primary sclerosing cholangitis.
MELD = model for end‐stage liver disease; HCC = hepatocellular carcinoma; non‐HCC = non‐hepatocellular carcinoma.
Early postoperative mortality rates.
| Study Cohorts n (%) | ||||
| Mortality Rates | n (%) | Pre‐MELD | Post‐MELD | p‐value |
| Overall | 23 (11.05) | 12 (16.43) | 11 (8.14) | 0.112 |
| Diagnostic Categories | ||||
| HCC | 5 (8.19) | 0 (0) | 5 (9.80) | 0.579 |
| Non‐HCC | 18 (12.24) | 12 (19.04) | 6 (7.14) | 0.054 |
| p‐value | 0.545 | |||
| MELD Score Risk Categories | ||||
| MELD <15 | 9 (9.67) | 5 (14.28) | 4 (6.89) | 0.289 |
| MELD 15‐20 | 10 (12.82) | 7 (23.33) | 3 (6.25) | 0.039 |
| MELD >20 | 4 (10.81) | 0 (0) | 4 (13.79) | 0.557 |
| p‐value | 0.994 | |||
Comparison between Pre vs. Post‐MELD cohorts using chi‐square tests.
Inter‐group comparisons were performed using the chi‐square test.
MELD = model for end‐stage liver disease; HCC = hepatocellular carcinoma; non‐HCC = non‐hepatocellular carcinoma.
Figure 1Overall patient survival (Kaplan‐Meier) before and after the model for end‐stage liver disease (MELD) criterion implementation. There was improved patient survival at three years (with a borderline statistical significance) among the post‐MELD cohort as compared to the pre‐MELD cohort (60.27% vs. 72.62%, p = 0.063, by the log‐rank test).
Figure 2Kaplan‐Meier analysis of patients stratified according to diagnosis (A) and model for end‐stage liver disease (MELD) score risk category (B). Inter‐group analysis showed no difference in patient survival at three years (p = 0.350 and p = 0.887, respectively, by the log‐rank test).
Stratified cumulative proportion surviving after liver transplantation.
| Cumulative Proportion Surviving (%) | |||||
| Groups and Categories | n (%) | 3 months | 6 months | 12 months | 36 months |
| Overall | |||||
| Pre‐MELD | 73 (35.10) | 77.62 | 72.57 | 65.75 | 60.27 |
| Post‐MELD | 135 (64.90) | 88.76 | 82.96 | 79.25 | 72.62 |
| p‐value | 0.036 | 0.066 | 0.028 | 0.063 | |
| HCC | |||||
| Pre‐MELD | 10 (16.39) | 100.00 | 100.00 | 90.00 | 80.00 |
| Post‐MELD | 51 (83.60) | 86.00 | 76.47 | 70.58 | 57.27 |
| p‐value | 0.217 | 0.090 | 0.174 | 0.141 | |
| Non‐HCC | |||||
| Pre‐MELD | 63 (42.85) | 73.98 | 68.21 | 61.90 | 57.14 |
| Post‐MELD | 84 (57.14) | 90.41 | 86.90 | 84.52 | 83.28 |
| p‐value | 0.009 | 0.005 | 0.001 | 0.001 | |
| MELD <15 | |||||
| Pre‐MELD | 35 (37.63) | 79.41 | 74.28 | 68.57 | 62.85 |
| Post‐MELD | 58 (62.36) | 87.71 | 82.75 | 79.31 | 70.35 |
| p‐value | 0.292 | 0.313 | 0.241 | 0.402 | |
| MELD 15‐20 | |||||
| Pre‐MELD | 30 (38.46) | 72.41 | 66.66 | 63.33 | 60.00 |
| Post‐MELD | 48 (61.53) | 91.66 | 85.41 | 85.41 | 78.32 |
| p‐value | 0.029 | 0.042 | 0.021 | 0.056 | |
| MELD >20 | |||||
| Pre‐MELD | 8 (21.62) | 87.50 | 87.50 | 62.50 | 50.00 |
| Post‐MELD | 29 (78.38) | 85.96 | 79.31 | 68.96 | 68.96 |
| p‐value | 0.874 | 0.588 | 0.785 | 0.604 | |
Kaplan‐Meier method.
Comparison between Pre‐ vs. Post‐MELD cohorts using the log‐rank test.
MELD = model for end‐stage liver disease; HCC = hepatocellular carcinoma; non‐HCC = non‐hepatocellular carcinoma.
Predictors of 3‐year post‐liver transplantation survival.
| Multivariate | ||||
| Variables | Univariate | Unadjusted | Allocation Criterion | Transplantation Era |
| Diagnostic categories | 0.350 | – | – | – |
| ABO blood group | 0.120 | 0.279 | 0.361 | 0.320 |
| Receptor gender | 0.635 | – | – | – |
| Recipient age (<55 vs. ≥55) | 0.973 | – | – | – |
| MELD (<15 vs.15‐20 vs. >20) | 0.887 | – | – | – |
| Child‐Pugh class | 0.400 | – | – | – |
| Donor age (<50 vs. ≥50) | 0.660 | – | – | – |
| Cold ischemia (<12 vs. ≥12) | 0.018 | 0.062 | 0.050 | 0.060 |
| Warm ischemia (<45 vs. ≥45) | 0.048 | 0.419 | 0.694 | 0.825 |
| Red blood cells (<5 vs. ≥5) | <0.001 | 0.002 | 0.002 | 0.003 |
| Platelets (yes vs. no) | 0.027 | 0.547 | 0.573 | 0.666 |
| Transplant rate (<5 vs. ≥5) | 0.424 | – | – | – |
| Hepato‐venous Reconstruction | 0.006 | 0.119 | 0.135 | 0.128 |
Continuous variables categorized as in parentheses.
Univariate analysis using the log‐rank test.
Multivariate analysis using the Cox‐proportional hazards model. This analysis was also adjusted to group the patients according to allocation criterion (pre‐MELD vs. post‐MELD) and transplantation era (first era vs. second era).
First era: 7/15/2003 – 8/28/2007; second era: 8/29/2007 – 7/14/2009.
HCC vs. non‐HCC patients.
Piggyback vs. conventional hepato‐venous anastomosis.
MELD = model for end‐stage liver disease; HCC = hepatocellular carcinoma; non‐HCC = non‐hepatocellular carcinoma.